Chapter 20 of 25
Nasopharyngeal carcinoma: a distinct disease
The nasopharynx is the space behind the nose and above the throat. Many nonkeratinizing nasopharyngeal cancers are associated with Epstein–Barr virus, or EBV. A neck lump, persistent one-sided ear symptoms, nasal blockage or bleeding can lead to diagnosis. Endoscopy and biopsy identify the tumour; MRI is particularly useful for local extent, and additional imaging assesses nodes and distant spread.
EBV testing in tumour tissue helps classification. Blood EBV DNA can help risk assessment and monitoring in appropriate settings, but must be interpreted alongside examination and imaging. A blood result alone does not prove or exclude recurrence. Nasopharyngeal carcinoma has its own staging system; the current AJCC Version 9 framework became effective for this site in 2025.
Radiotherapy is central to curative treatment. Some early cases can be treated with radiation alone, while more advanced disease commonly requires cisplatin-based chemoradiotherapy. In selected locoregionally advanced cases, induction gemcitabine-cisplatin before chemoradiotherapy has randomized evidence. The 2019 trial and subsequent follow-up supported improved outcomes compared with chemoradiotherapy alone in the studied population.
Recurrent or metastatic nasopharyngeal cancer has specific systemic options. The US FDA approved toripalimab with cisplatin and gemcitabine for first-line metastatic or recurrent locally advanced disease in 2023, and toripalimab alone after progression on platinum in qualifying recurrent unresectable or metastatic disease. Other PD-1 approaches depend on region and evidence. These indications should not be transferred to ordinary oral cavity squamous cancer.
Salivary gland cancers: identify the histology first
Cancer may arise in major glands such as the parotid or in small glands throughout the mouth and throat. Mucoepidermoid carcinoma, adenoid cystic carcinoma, salivary duct carcinoma and secretory carcinoma differ greatly. Specialist pathology review may change the diagnosis and treatment. A slow-growing tumour is not necessarily harmless; some types recur late or spread along nerves.
Surgery is usually central for resectable disease, with postoperative radiation considered according to grade, stage, margins, nerve involvement and other risks. Facial-nerve function matters especially for parotid surgery. Routine addition of chemotherapy to postoperative radiation is not established for all salivary cancers and should not be assumed from squamous-cell practice.
In advanced disease, HER2 and androgen-receptor testing can guide selected salivary duct cancer treatments. NTRK-fusion testing is especially relevant in secretory carcinoma; other alterations may justify sequencing or trial referral. An actionable result must be connected to the correct test and treatment evidence. Some indolent metastatic cancers may be observed until symptoms or progression warrant systemic treatment.
Sinonasal cancers: one location, many diagnoses
Persistent one-sided nasal blockage, recurrent nosebleeds, facial pain, swelling or eye symptoms require assessment. Endoscopy with biopsy establishes the tissue type. CT shows bone involvement while MRI helps assess soft tissues, the skull base, eyes and nerves. Symptoms near the eye or brain can require prompt specialist evaluation.
Sinonasal squamous cancer, adenocarcinoma, olfactory neuroblastoma, mucosal melanoma and other uncommon entities do not share one drug regimen. Treatment may include endoscopic or open surgery, radiation and selected systemic therapy. Skull-base expertise is often needed. The team weighs clearance against effects on vision, smell, appearance and neurological function; selected cases may benefit from particle therapy after planning comparison.
Cancer of unknown primary presenting in neck nodes
Sometimes biopsy shows cancer in a neck node but the starting site is not obvious. This does not mean that the investigation has failed or that treatment is impossible. The work-up can include detailed examination, flexible endoscopy, appropriate imaging and PET-CT, HPV-related testing and EBV testing when indicated. Examination under anaesthesia and directed tonsil or tongue-base procedures may identify a small hidden primary.
A cystic neck lump in an adult must not automatically be dismissed as a harmless cyst. HPV-associated oropharyngeal cancer can present this way. The diagnostic team should plan tissue sampling appropriately rather than proceeding to an unplanned open operation.
Treatment depends on the nodal extent, likely origin, viral markers and previous care. Options can include neck surgery followed by risk-adapted radiation or chemoradiotherapy, or a definitive radiation-based approach. Identifying the primary can sometimes help tailor the treatment fields. The aim is to control cancer while limiting unnecessary exposure to swallowing and salivary structures.
References and evidence review
- Geiger et al. ASCO guideline: salivary gland malignancy (2021)
- Zhang et al. Gemcitabine-cisplatin induction in nasopharyngeal carcinoma (2019)
- Zhang et al. Final survival analysis (2022)
- FDA: toripalimab approval for nasopharyngeal carcinoma (2023)
- NCI: Treatment of Head and Neck Cancer in Adults, current PDQ summaries
Evidence/editorial check: 25 October 2026. AI-assisted preparation is distinct from individual physician review. See the linked review policy for source-access limits and review status. Regulatory indications, reimbursement and availability vary by country. Trial results alone do not establish approval everywhere; your treating team should confirm the applicable current guidance.